Clinical trial
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
Active, not recruiting · Not applicable · 1 countries · Registry ID NCT06980623
Active, not recruitingNot applicableObservational
What this study is about
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot listed
ConditionType 2 Diabetes, Heart Failure
Full registry criteria
Inclusion Criteria: * Patients who are new users of tirzepatide or new users of semaglutide * Patients with diagnosis of T2D and HFpEF, i.e., EF \>= 45%. * Age \>= 18 years old * Patients with continuous health plan enrollment before and including the treatment initiation date Exclusion Criteria: * Patients with missing age or sex information * Patients with type 1 diabetes mellitus, secondary or gestational diabetes * History of diabetes related complications * Patients with related chronic diseases. * History of gastrointestinal conditions. * Previous exposure to other GLP-1RA and pramlintide * Patients with prescription dispensing for both tirzepatide and semaglutide on cohort entry date
Treatments and study arms
Tirzepatide
Drug
Exposure group
Semaglutide
Drug
Referent group
Primary outcomes
Hospitalization for heart failure and all-cause mortalityFrom treatment initiation to end of follow up, up to 48 months.
Cardiovascular outcome includes hospitalization for HF and all-cause mortality
Study locations
1 locations were listed when this page was built. The first 40 are shown.
Brigham and Women's Hospital🇺🇸 Boston, Massachusetts, United States